Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Research & Development (2016 - 2025)

Zevra Therapeutics' Research & Development history spans 11 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Research & Development fell 68.63% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $12.7 million, down 69.73%, while the annual FY2025 figure was $12.7 million, 69.73% down from the prior year.
  • Research & Development reached $2.6 million in Q4 2025 per ZVRA's latest filing, down from $3.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $19.8 million in Q4 2022 to a low of $2.2 million in Q3 2021.
  • Average Research & Development over 5 years is $7.1 million, with a median of $5.4 million recorded in 2022.
  • Peak YoY movement for Research & Development: soared 604.98% in 2022, then crashed 73.46% in 2025.
  • A 5-year view of Research & Development shows it stood at $2.8 million in 2021, then skyrocketed by 604.98% to $19.8 million in 2022, then crashed by 42.33% to $11.4 million in 2023, then dropped by 26.87% to $8.4 million in 2024, then tumbled by 68.63% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Research & Development are $2.6 million (Q4 2025), $3.4 million (Q3 2025), and $3.4 million (Q2 2025).